Tokushima University / Educator and Researcher Directory --- Haji, Keiko

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis., Respiratory Research, Vol.24, No.1, 148, 2023. (Summary) These findings suggest that targeting PLK1 may be a novel therapeutic approach for pulmonary fibrosis by inhibiting lung fibroblast proliferation without affecting lung epithelial cells. In addition, while in silico screening is useful, it is essential to fully determine the biological activities of candidates by wet-lab validation studies. (Keyword) Mice / Animals / Drug Repositioning / Thiophenes / Benzimidazoles / Lung / Idiopathic Pulmonary Fibrosis / Fibroblasts / Bleomycin (Tokushima University Institutional Repository) ● Metadata: 119057 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12931-023-02446-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37269004 ● Search Scopus @ Elsevier (PMID): 37269004 ● Search Scopus @ Elsevier (DOI): 10.1186/s12931-023-02446-x (Tokushima University Institutional Repository: 119057, DOI: 10.1186/s12931-023-02446-x, PubMed: 37269004)
2.	Seiya Ichihara, Hirokazu Ogino, Hiroto Yoneda, Keiko Haji, Kozo Kagawa, Kojin Murakami, Masato Mima, Yu Aoi, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody., Respiratory Medicine Case Reports, Vol.41, 101797, 2023. (Summary) A man with non-small-cell lung cancer who was negative for anti-nuclear antibodies was admitted for dyspnea after immune checkpoint inhibitor (ICI) administration. Computed tomography (CT) showed complexed radiologic features, including subpleural and basal predominant reticular shadow with cystic structures and peribronchovascular consolidation. Although we treated him with high-dose steroid under a diagnosis of ICI-related pneumonitis, he developed acute exacerbation of pneumonitis with progressive fibrosis and volume loss. A re-evaluation identified anti-aminoacyl-tRNA synthetase antibody in the serum collected before ICI administration. This case highlights the importance of re-evaluating pre-existing autoimmune disorders in patients who develop ICI-related pneumonitis with atypical radiologic features. (Tokushima University Institutional Repository) ● Metadata: 119054 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.rmcr.2022.101797 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36583061 ● Search Scopus @ Elsevier (PMID): 36583061 ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2022.101797 (Tokushima University Institutional Repository: 119054, DOI: 10.1016/j.rmcr.2022.101797, PubMed: 36583061)
3.	Makoto Tobiume, Atsushi Mitsuhashi, Atsuro Saijo, Hirokazu Ogino, Tania Afroj, Hirohisa Ogawa, Hisatsugu Goto, Seidai Satou, Akane Abe, Keiko Haji, Ryohiko Ozaki, Hiromitsu Takizawa and Yasuhiko Nishioka : Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancer., Oncology Letters, Vol.24, No.5, 417, 2022. (Summary) Fibrocytes, which are bone marrow-derived collagen-producing cells, have been reported to be involved in pathogenesis of pulmonary fibrosis. Our previous study reported that tumor-infiltrating fibrocytes play a role in tumor progression and drug resistance in lung cancer. The present study therefore examined chemotactic factors for fibrocytes in tissues of non-small cell lung cancer (NSCLC) and their prognostic significance. Surgically resected tumor tissues were examined for the expression of chemotactic factors, including C-X-C motif chemokine 12 (CXCL12), CCL2, platelet-derived growth factor (PDGF)-AA and PDGF-BB, as well as tumor-infiltrating fibrocytes by immunostaining. The chemotactic ability of fibrocytes in response to each factor was evaluated using a migration assay by counting the migrated cells microscopically, and expression of receptors for chemotactic factors were analyzed by flow cytometry. The expression of CXCL12, but not CCL2, PDGF-AA, or PDGF-BB, was associated with the number of tumor-infiltrating fibrocytes in lung adenocarcinoma (LUAD), but not lung squamous cell carcinoma (LUSQ). In addition, patients with an increased expression of CXCL12 in LUAD but not LUSQ showed a significantly poorer prognosis compared with those with a decreased expression. However, the expression of CCL2, PDGF-AA and PDGF-BB was not correlated with the prognosis of patients with NSCLC. The number of fibrocytes was associated with a poor prognosis in LUAD. Fibrocytes derived from the peripheral blood of healthy subjects as well as patients with lung cancer expressed higher levels of CXCR4 compared with CCR2, PDGF and receptor-α and receptor-β. Overall, these results suggested that targeting tumor-infiltrating fibrocytes via the CXCL12/CXCR4 axis may be a useful strategy for controlling the progression of NSCLC, particularly LUAD. (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2022.13537 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36245829 ● Search Scopus @ Elsevier (PMID): 36245829 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13537 (DOI: 10.3892/ol.2022.13537, PubMed: 36245829)
4.	Keiko Haji, Seidai Satou, Hiroto Yoneda, Toshihiko Nisisho, Hiroshi Nokihara and Yasuhiko Nishioka : Multidisciplinary treatment of skeletal muscle metastasis from lung cancer: A case of triceps muscle metastasis of lung squamous cell cancer., Respiratory Medicine Case Reports, Vol.33, 2021. (Summary) A 62-year-old Japanese man presented a hard and painful intramuscular mass in the right upper arm during the chemotherapy for lung squamous cell carcinoma. Initially, this mass containing fluid accumulation was treated by radiotherapy and antibiotics as a muscle metastasis suspected to be complicated with local infection. However, because the swelling and pain of his right arm did not improve, he underwent a surgical debridement of the mass. These local treatments succeeded in relieving the patient's symptoms for a while. However, after temporary remission, the recurrence tumor developed the paralysis of right radial nerve and ulnar nerve in his upper arm. Despite further combined therapy including drainage, additional radiotherapy, and chemotherapy, paralysis made his performance status deteriorated. He was eventually discontinued aggressive treatment due to worsened general condition. We herein report a case of lung cancer followed unusual course due to muscle metastasis in the triceps muscle. Because the paralysis caused by muscle metastasis can be the factor to deteriorate the performance status of patient, the combined therapy including antibiotics, debridement, radiotherapy and chemotherapy as early as possible should be considered to avoid its risk. (Tokushima University Institutional Repository) ● Metadata: 117385 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.rmcr.2021.101470 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34401306 ● Search Scopus @ Elsevier (PMID): 34401306 ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2021.101470 (Tokushima University Institutional Repository: 117385, DOI: 10.1016/j.rmcr.2021.101470, PubMed: 34401306)

Proceeding of International Conference:

1.	Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Murakami Kojin, Yuya Yamashita, Danzan NandinErdene, Bando Hiroki, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka : A novel senolytic drug, ARV-825, ameliorates experimental lung fibrosis, ERS International Congress 2023, Milano, Sep. 2023.
2.	Hiroki Bando, Seidai Satou, Hirohisa Ogawa, Kazuya Koyama, Murakami Kojin, Yuya Yamashita, Danzan Nandin-Erdene, Keiko Haji, Nobuhito Naito, Hiroshi Kawano and Yasuhiko Nishioka : Anamorelin, a ghrelin receptor agonist, inhibited the allergic airway inflammation in mice, ERS International Congress 2023, Milano, Sep. 2023.
3.	Murakami Kojin, Nishimura Haruka, Hiroshi Kawano, Danzan Nandin-Erdene, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kazuya Koyama, Seidai Satou and Yasuhiko Nishioka : Analysis of the Anti-fibrotic Potential of JAK Inhibitors in a Bleomycin-induced Pulmonary Fibrosis Model, ATS 2023, Washington, DC, May 2023.
4.	Kazuya Koyama, Seidai Satou, Hiroshi Kawano, Hiroshi Kawano, Atsushi Mitsuhashi, Murakami Kojin, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hirohisa Ogawa and Yasuhiko Nishioka : Evaluation of fibrocytes in silica-induced and bleomycin-induced pulmonary fibrosis model in mice by single cell RNA-seq analysis, APSR 2022, Seoul, Nov. 2022.
5.	Imakura Takeshi, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Murakami Kojin, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : Computational drug repositioning and wet-lab validation approach identifies polo-like kinase inhibitors as potential therapeutics for pulmonary fibrosis, ERS International Congress 2022, Barcelona, Sep. 2022.
6.	Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka : A Novel Senolytic Agent, ARV-825, Ameliorates Bleomycin-InducedPulmonary Fibrosis in Mice, ATS 2022 International Conference, San Francisco, May 2022.
7.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : Computational Drug Repositioning Approach Identifies Polo-Like KinaseInhibitors as Potential Therapeutics for Pulmonary Fibrosis, ATS 2022 International Conference, San Francisco, May 2022.
8.	Kazuya Koyama, Hiroshi Kawano, Atsushi Mitsuhashi, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Seidai Satou, Hirohisa Ogawa and Yasuhiko Nishioka : Single Cell RNA-seq Analysis of Fibrocytes in Silica Induced Mouse Pulmonary Fibrosis Model, ATS 2022 International Conference, San Francisco, May 2022.

Proceeding of Domestic Conference:

1.	Noriko Bando, Hiroki Bandoh, Keiko Haji, 美馬正人, Asami Fukuya, Nobuhito Naito, Ryohiko Ozaki, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Satoshi Sakaguchi, Masaki Hanibuchi and Yasuhiko Nishioka : 当科における重症喘息に対する生物学的製剤の治療効果の検討, 第268回徳島医学会学術集会, Mar. 2024.
2.	Ryoko Suzue, Hiroki Bandoh, Keiko Haji, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 抗横紋筋抗体陽性の重症irAE筋炎・心筋炎に対して早期の集学的治療が奏効した肺扁平上皮癌の1例, 第69回日本呼吸器学会中国・四国地方会, Dec. 2023.
3.	寺澤翠, Hiroki Bandoh, Keiko Haji, Hiroto Yoneda, Hirokazu Ogino, 岡田直子, Takashi Kawanaka, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : ペプチド受容体放射性核種療法が奏効した左下葉原発進行期非定型カルチノイドの1例, 第69回日本呼吸器学会中国・四国地方会, Dec. 2023.
4.	Yu Aoi, Hiroki Bandoh, Keiko Haji, 高橋啓輝, Hiroto Yoneda, Akane Abe, Seidai Satou, Momoyo Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : 気管支鏡検査で診断したCOVID-19関連肺アスペルギルス症の1例, 第32回日本呼吸器内視鏡学会中国四国支部会, Dec. 2023.
5.	中西渓介, Hiroki Bandoh, Keiko Haji, 小倉祐一郎, 美馬正人, Nobuhito Naito, Akane Abe, 川真田純, 杉浦宏, Seidai Satou, Momoyo Azuma, Masaki Hanibuchi, Koichi Sairyo and Yasuhiko Nishioka : 結核性脊椎炎の治療中にparadoxical responseとして皮下膿瘍が出現した1例, 第74 回日本結核・非結核性抗酸菌症学会中国四国支部会, Dec. 2023.
6.	Yuta Isomura, Hiroki Bandoh, Keiko Haji, Nobuhito Naito, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 悪性リンパ腫の治療経過中に発症したβ-Dグルカン陰性ニューモシスチス肺炎の1例, 第129回日本内科学会四国地方会, Dec. 2023.
7.	山本浩生, Hiroki Bandoh, Keiko Haji, Yuya Yamashita, Nobuhito Naito, Seidai Satou, Hiroshi Kawano, Masaki Hanibuchi and Yasuhiko Nishioka : ステロイド抵抗性の気道病変に対してシクロホスファミドが著効した再発性多発軟骨炎の1例, 第129回日本内科学会四国地方会, Dec. 2023.
8.	Seidai Satou, Hirohisa Ogawa, Kojin Murakami, Yuya Yamashita, Keiko Haji, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka : BRD4 阻害剤 ARV825 の線維化関連遺伝子の発現抑制と老化細胞除去を介した抗線維化効果の検討, 第3回日本びまん性肺疾患研究会, Sep. 2023.
9.	Keiko Haji, Seidai Satou, Hirohisa Ogawa, Kojin Murakami, Yuya Yamashita, Kazuya Koyama, Hiroshi Kawano, 小林克利, 諸星俊郎 and Yasuhiko Nishioka : オートタキシン阻害作用を有する 2ccPA の肺線維症における有効性の検討, 第3回日本びまん性肺疾患研究会, Sep. 2023.
10.	原田紗希, Hiroki Bandoh, Keiko Haji, Nobuhito Naito, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 当院において外科治療を施行した肺Mycobacterium avium complexの検討, 第267回徳島医学会学術集会, Aug. 2023.
11.	寺澤翠, Hiroki Bandoh, Keiko Haji, 小路貴俊, Hiroto Yoneda, Seidai Satou, Hiroshi Kawano, Masaki Hanibuchi and Yasuhiko Nishioka : シクロスポリンが有効であった血清IL-18高値の重症成人発症スティル病の1例, 第128回日本内科学会四国地方会, Jul. 2023.
12.	中西渓介, Hiroki Bandoh, Keiko Haji, 松村有悟, 稲葉香織, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : Carboplatin+etoposideや放射線治療に不応もnab-paclitaxelが奏効した肺原発大細胞神経内分泌癌の1例, 第128回日本内科学会四国地方会, Jul. 2023.
13.	山本浩生, Hiroki Bandoh, Keiko Haji, Michihiro Kunishige, 梶本達也, Kazuya Koyama, Kozo Kagawa, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 自然経過で嚢胞性画像変化および呼吸機能の改善を認めた重症COVID-19の1例, 第68回日本呼吸器学会中国・四国地方会, Jul. 2023.
14.	多田里穂, Hiroki Bandoh, Keiko Haji, 新居香織, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 抗PD-L1抗体投与により腫瘍随伴性小脳変性症が顕在化した小細胞肺癌の1例, 第61回日本肺癌学会中国・四国支部学術集会, Jul. 2023.
15.	遠藤裕美, Hiroki Bandoh, Keiko Haji, 高橋啓輝, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 包括的ゲノムプロファイリングにより診断し得たEGFR Exon19欠失変異陽性肺腺癌の1例, 第61回日本肺癌学会中国・四国支部学術集会, Jul. 2023.
16.	Kojin Murakami, Seidai Satou, Yuya Yamashita, Keiko Haji, 坂東弘基, Nobuhito Naito, Kazuya Koyama, Hiroshi Kawano, 稲村典昭, 蓮見惠司 and Yasuhiko Nishioka : 新規可溶性エポキシヒドロラーゼ阻害薬SMTP-44Dの肺線維症に対する有効性の検討, 第63回日本呼吸器学会学術講演会, Apr. 2023.
17.	松村有悟, Keiko Haji, 鈴江涼子, Hiroto Yoneda, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Hirohisa Ogawa, Masaki Hanibuchi and Yasuhiko Nishioka : 血清Krebs von den Lungen-6 が高値を示した悪性胸膜中皮腫の1例, 第127回日本内科学会四国地方会, Dec. 2022.
18.	新居香織, Keiko Haji, Yu Aoi, Yuya Yamashita, Nobuhito Naito, Hirokazu Ogino, Hiroshi Kawano, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 関節炎を呈したACTH 単独欠損症の1例, 第127回日本内科学会四国地方会, Dec. 2022.
19.	Kenya Miyamoto, Keiko Haji, 原田紗希, 鈴江涼子, Akane Abe, Momoyo Azuma, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 当院における肺MAC症に対するアジスロマイシン併用療法の有効性・安全性の検討, 第73回日本結核・非結核性抗酸菌症学会中国四国支部会, Dec. 2022.
20.	森彩花, Keiko Haji, Yu Aoi, Kenya Miyamoto, Kojin Murakami, Yuki Tsukazaki, Hiroki Bandoh, Ryohiko Ozaki, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 免疫チェックポイント阻害薬使用後に肺胞出血をきたした1例, 第31回日本呼吸器内視鏡学会中国四国支部会, Dec. 2022.
21.	寺澤翠, Keiko Haji, 市原聖也, Yuya Yamashita, Asami Fukuya, Nobuhito Naito, Hiroto Yoneda, Kozo Kagawa, Hirokazu Ogino, Hiroshi Kawano, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 抗PD-L1抗体投与後に顕在化した抗ARS抗体陽性間質性肺炎の1例, 第67回日本呼吸器学会中国・四国地方会, Dec. 2022.
22.	中西颯斗, Keiko Haji, 松村有悟, Atsushi Mitsuhashi, 小川瑛, Takeshi Imakura, 美馬正人, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino, Satoshi Sakaguchi, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 同時に異なる3つの組織型を認めた多発性肺癌の1例, 第67回日本呼吸器学会中国・四国地方会, Dec. 2022.
23.	Nobuhito Naito, 西村春佳, Yuya Yamashita, Kojin Murakami, Keiko Haji, Kazuya Koyama, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Masaki Hanibuchi and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスを用いたJAK阻害薬の抗線維化効果についての検討, 第50回日本臨床免疫学会総会, Oct. 2022.
24.	中西颯斗, Keiko Haji, Yohhei Yabuki, 新居香織, 高丸利加子, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : セルペルカチニブが奏功したRET融合遺伝子陽性肺腺癌の1例, 第265回徳島医学会学術集会, Jul. 2022.
25.	小倉佑一朗, Keiko Haji, 近藤健介, Kenji Otsuka, Hirokazu Ogino, Kazuya Koyama, 村上行人, Hiroki Bandoh, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 間質性肺炎への治療反応性から肝肺症候群の併存が顕在化した一例, 第66回日本呼吸器学会中国・四国地方会, Jul. 2022.
26.	松村有悟, Keiko Haji, 美馬正人, Yohhei Yabuki, Kenji Otsuka, Hiroto Yoneda, Hiroshi Nokihara, Hirokazu Ogino, Ryohiko Ozaki, 塚崎佑貴, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 小細胞肺癌への形質転換を認めたEGFR遺伝子変異陽性肺腺癌の3例, 第60回日本肺癌学会中国・四国支部学術集会, Jul. 2022.
27.	新居香織, Yohhei Yabuki, Keiko Haji, 高丸利加子, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : セルペルカチニブが奏効したRET融合遺伝子陽性肺腺癌の1例, 第60回日本肺癌学会中国・四国支部学術集会, Jul. 2022.
28.	Keiko Haji, Yohhei Yabuki, 美馬正人, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : MET阻害薬が著効したMET遺伝子 exon14 skipping 変異陽性肺扁平上皮癌の1例, 第126回日本内科学会四国地方会, Jun. 2022.
29.	美馬正人, Seidai Satou, 原田紗希, 鈴江涼子, Yuya Yamashita, Ryohiko Ozaki, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 抗ARS抗体陽性間質性肺疾患の胸部画像所見の検討, 第62回日本呼吸器学会学術講演会, Apr. 2022.
30.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : In silico解析により同定されたPLK阻害剤のブレオマイシン誘発肺線維症モデルマウスにおける効果の検討, 第62回日本呼吸器学会学術講演会, Apr. 2022.
31.	中内友合江, YABUKI Yohhei, Keiko Haji, Hiroto Yoneda, Atsushi Mitsuhashi, 青井優, 石田卓也, 村上尚哉, Hirokazu Ogino, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : Tepotinibが著効したMET遺伝子exon14 skipping変異陽性肺腺癌の1例, 第59回日本肺癌学会中国・四国支部学術集会, Aug. 2021.

Assistant Professor : Haji, Keiko

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference: